Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy
Theranostics · 2024 · 14 (9) · 3509-3525
DOI: 10.7150/thno.96946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Xiao-Yan Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Eye Hospital, Nanjing Medical University, Nanjing 210000, China. Hauptthemen laut MEDLINE: Glycolysis, Endothelial Cells, Choroidal Neovascularization. Die Arbeit wurde bisher 27-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale
Current treatments for ocular angiogenesis primarily focus on blocking the activity of vascular endothelial growth factor (VEGF), but unfavorable side effects and unsatisfactory efficacy remain issues. The identification of novel targets for anti-angiogenic treatment is still needed.
Methods
We investigated the role of tsRNA-1599 in ocular angiogenesis using endothelial cells, a streptozotocin (STZ)-induced diabetic model, a laser-induced choroidal neovascularization model, and an oxygen-induced retinopathy model. CCK-8 assays, EdU assays, transwell assays, and matrigel assays were performed to assess the role of tsRNA-1599 in endothelial cells. Retinal digestion assays, Isolectin B4 (IB4) staining, and choroidal sprouting assays were conducted to evaluate the role of tsRNA-1599 in ocular angiogenesis. Transcriptomic analysis, metabolic analysis, RNA pull-down assays, and mass spectrometry were utilized to elucidate the mechanism underlying angiogenic effects mediated by tsRNA-1599. Results: tsRNA-1599 expression was up-regulated in experimental ocular angiogenesis models and endothelial cells in response to angiogenic stress. Silencing of tsRNA-1599 suppressed angiogenic effects in endothelial cells in vitro and inhibited pathological ocular angiogenesis in vivo. Mechanistically, tsRNA-1599 exhibited little effect on VEGF signaling but could cause reduced glycolysis and NAD+/NADH production in endothelial cells by regulating the expression of HK2 gene through interacting with YBX1, thus affecting endothelial effects.
Conclusions
Targeting glycolytic reprogramming of endothelial cells by a tRNA-derived small RNA represents an exploitable therapeutic approach for ocular neovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Eye Hospital, Nanjing Medical University, Nanjing 210000, China.
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
- The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210000, China.
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Zitieren
APA
Han, X. Y., Kong, L. J., Li, D., Tong, M., Li, X. M., Zhao, C., Jiang, Q., & Yan, B. (2024). Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy. Theranostics, 14(9), 3509-3525. https://doi.org/10.7150/thno.96946
Vancouver
Han XY, Kong LJ, Li D, Tong M, Li XM, Zhao C, et al. Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy. Theranostics. 2024;14(9):3509-3525. doi:10.7150/thno.96946
BibTeX
@article{Han2024,
author = {Han, Xiao-Yan and Kong, Ling-Jie and Li, Duo and Tong, Ming and Li, Xiu-Miao and Zhao, Chen and Jiang, Qin and Yan, Biao},
title = {Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy},
journal = {Theranostics},
year = {2024},
volume = {14},
number = {9},
pages = {3509--3525},
doi = {10.7150/thno.96946}
}
EUVIMED